zocor

AstraZeneca Stock Jumps After Court Ruling on Crestor

AstraZeneca shares surged by almost 9% Tuesday after the company scored a win in court regarding the patent for its cholesterol treatment, Crestor. The ruling means that AstraZeneca won't have to worry about generic competition for its multibillion-dollar statin until 2016.

FDA Warns Against High Doses of Zocor

The U.S. Food and Drug Administration issued a warning Friday about using high doses of the popular cholesterol-lowering drug Zocor -- generic name simvastatin -- and the increased risk of serious muscle injury.

Crestor Backed by FDA for Patients With Normal Cholesterol

AstraZeneca scored a win on Tuesday, when a Food and Drug Administration advisory panel recommended broader use of Crestor, the company's cholesterol-lowering drug. The panel recommended that those with low cholesterol use the drug, following studies finding that Crestor reduces the risk of heart disease even in those with normal cholesterol levels.